conditions; in this regard, we believe that similar studies in myelofibrotic transformation of MPN, blast phase of chronic myeloid leukemia and MDS patients without isolated del(5q) will be of value.
Acute monoblastic leukemia, also designated as AML5 subtype, is characterized by accumulation of monoblastic-like cells (AML5 blasts), which terminal differentiation is blocked. The AML5 subtype poorly responds to chemotherapy and still has bad prognosis. We have previously reported that CD44-ligation with specific monoclonal antibodies (mAbs) can reverse differentiation blockage in AML5 subtype, 1 providing strong basis for the development, in AML5, of a CD44-targeted differentiation therapy that could be as efficient as that with retinoic acid in the promyelocytic AML subtype.
By monitoring differentiation using the gradual increase in expression of CD11b and CD14 monocytic-lineage antigens, we have recently shown that CD44-ligation triggers in AML5 blasts, a burst of cytokine synthesis, and that granulocytemacrophage colony-stimulating factor(GM-CSF) and interleukin (IL)-8 are required to increase the expression of CD14. 2 However, the mechanisms involved in CD44-induced differentiation, and especially in differentiating cytokine synthesis, are still unknown. Here, using the THP-1 monoblastic cell line as a model of AML5 blasts, and Hermes-3 anti-CD44 mAb (H3) to induce its differentiation, we show that CD44-ligation induces, through extracellular signal-regulated kinases (ERK)1/2 pathway, the synthesis of cytokines tumor necrosis factor (TNF)-a and IL-6 required for monocytic differentiation of these leukemic cells. 
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Like CD44-ligated AML5 blasts, THP-1 cells differentiate after addition of the H3 anti-CD44 mAb and synthesize cytokines. Indeed, H3-treated THP-1 cells display, at day 3, increased levels of both differentiation antigens CD11b (67%±6% CD11b þ cells vs 30% ± 3% in isotypic-treated controls) and CD14 (38% ± 4% CD14 þ cells vs o5% in isotypic-treated controls), as shown by flow cytometry analysis. Moreover, enzyme-linked immunosorbent assay (ELISA) assay shows that, at 24 h, H3-treated THP-1 cells secrete a burst of cytokines including GM-CSF (194 ± 36 pg/ ml), IL-6 (86±15 pg/ml), IL-8 (96±12 pg/ml) and TNF-a (1050± 23 pg/ml), all of which are also synthesized by CD44-ligated AML5 blasts. These cytokines are not secreted by IgG-treated control THP-1 cells. Next, we have examined which of these secreted cytokines are necessary for inducing the expression of differentiation antigens CD11b and CD14 in H3-treated THP-1 cells. Using specific function-inhibiting mAbs, we show that functional inhibition of TNF-a alone fully abrogates the increase in CD11b expression, whereas independent or combined inhibition of the other cytokines has no effect ( Figure 1b) . Besides, functional inhibition of TNF-a or IL-6 inhibits the rise in CD14 expression by approximately 30% (Figure 1a ), and by up to 55% when added together. Blockage of either GM-CSF or IL-8 has no effect. Therefore, in H3-treated THP-1 cells, TNF-a alone is required to increase the expression of CD11b, whereas in contrast, both TNF-a and IL-6 are required to induce CD14 expression. In line with this result, it is well established that TNF-a and IL-6 activate distinct signaling pathways, nuclear factor (NF)-kappaB 3 and Janus Kinases/Signal Transducers and Activators of Transcription (JAK/STAT), 4 respectively. We have then asked whether secreted doses of TNF-a and IL-6 are sufficient to increase the expression of CD11b and CD14 in THP-1 cells. As shown in Figure 1b , exogenous addition of 1 ng/ml (secreted dose) of TNF-a alone is sufficient to increase the expression of CD11b, although the amount of 10 ng/ml TNF-a is needed to increase it as efficiently as H3. These results suggest that, in H3-treated THP-1 cells, secreted TNF-a alone is sufficient to increase the expression of CD11b. Besides, exogenous TNF-a or IL-6 added independently, at secreted doses (1 ng/ml and 0.1 ng/ml, respectively), cannot induce CD14 expression, even if 100-times higher doses are added. Only the combined addition of both TNF-a and IL-6, at higher doses than the secreted ones, succeeds to induce CD14. Altogether, these results also suggest that autocrine cytokines, acting locally, are more efficient than the exogenously added ones.
Interestingly, the mitogen-activated protein kinase (MAPK) family of serine/threonine kinases, which includes ERKs, JNKs (c-Jun N-terminal kinases) and p38MAPK, has an important role in the regulation of both monocytic differentiation, 5 and induction of cytokine synthesis by activated macrophages. 6 Accordingly, we asked whether MAPK has a role in CD44-induced monocytic differentiation and differentiating cytokine synthesis by THP-1 leukemic cells.
First, we have examined whether a MAPK is involved in the differentiation of H3-treated THP-1 cells. As shown in Figure 2a , blocking JNK (SP600125 inhibitor) or p38MAPK (SB203580 inhibitor) does not inhibit the increase in CD11b or CD14 expression in these cells. In contrast, blocking ERK1/2 activation with the mitogen-activated ERK kinase (MEK) inhibitors U0126 or PD98059, completely inhibits it. None of these inhibitors have noticeable inhibitory effect on cell survival. In addition, when ERK1 and ERK2 are partially depleted by specific siRNA, CD11b and CD14 expressions are significantly less increased Letters to the Editor after addition of H3 (Figure 2b ). Cell survival is not significantly affected by the small interfering RNA (siRNA) treatment. These results show that ERK1/2 is essential for CD44-induced differentiation of THP-1 cells. The CD44-stimulated signaling pathway leading to ERK1/2 activation in THP-1 cells, remains to be elucidated. Preliminary data (not shown) suggest that it involves PKC and Src kinases. ERK activation occurs through phosphorylation. Time-course analysis shows that whereas amount of total ERK remains unchanged, ERK1/2 phosphorylation is detected from 30 min to approximately 8 h after addition of H3 (Supplementary Figure 1a) . Thereafter, the level of phospho-ERK1/2 declines. Level and duration of H3-induced phosphorylation are similar as the ones induced by PMA, a strong inducer of THP-1 cell differentiation. In contrast, the anti-CD44 mAb H90, that does not induce differentiation of THP-1 cells, 7 only induces transient ERK1/2 phosphorylation at 1 h. Moreover, H3-induced increase of differentiation antigens CD11b and CD14 is completely abrogated when U0126 inhibitor is added at 1-8 h after H3 (Supplementary Figure 1b) , indicating that ERK1/2 activation during 8 h is critical for differentiation of CD44-ligated THP-1 cells.
Second, we have analyzed whether ERK1/2 is required for TNF-a and IL-6 synthesis by H3-treated THP-1 cells. Quantitative reverse transcriptase-PCR (Q-RT-PCR) analysis (Figure 3a) shows that mRNA level of IL-6 and of TNF-a genes increases, respectively, from 1 to 12 h, and from 1 to 6 h after CD44-ligation. Addition of U0126 fully inhibits expression of both TNF-a and IL-6 genes throughout these durations, indicating that it is ERK1/2 dependent. We further examine whether TNF-a /IL-6 protein secretion is also ERK1/2 dependent. Using ELISA assay, we detect secreted IL-6 from 6 h after CD44-ligation, and its amount regularly increases for 24 h (Figure 3b) . Secreted TNF-a is detected from 1 h after CD44-ligation, and its amount is maximum at 6-12 h. U0126 fully inhibits both TNF-a and IL-6 secretion. As expected, TNF-a and IL-6 proteins are not detected in the culture medium of IgGtreated THP-1 cells. Therefore, these results show for the first time that CD44 ligation induces TNF-a and IL-6 synthesis through ERK1/2 signaling in THP-1 cells. Although p38MAPK has a predominant role in cytokine synthesis by activated macrophages, there is increasing evidence that ERK1/2 is also essential for TNF-a and IL-6 synthesis, and that the respective contribution of ERK1/2 and p38MAPK depends on the stimulus and on the cell type. 8 Therefore, further studies are required to determine whether the key-role of ERK1/2 in TNF-a/IL-6 synthesis is specific for CD44 activation, or/and for THP-1 leukemic cells.
In conclusion, the results presented here have emphasized the important role of autocrine cytokine synthesis in CD44-induced differentiation of monoblastic leukemia cells. Interestingly, CD44-ligation also induces a burst of cytokine synthesis in Letters to the Editor AML5 blasts, but different cytokines are involved in CD44-induced differentiation of AML5 blasts (IL-8 and GM-CSF) and THP-1 cells (TNF-a and IL-6). This suggests that distinct AML5 cases are responsive to distinct cytokines. For this reason, we believe that the noteworthy ability of CD44 to activate a wide range of autocrine cytokine synthesis, explains, at least in part, why CD44-targeting is so successful in inducing differentiation of AML5 blasts.
